nodes	percent_of_prediction	percent_of_DWPC	metapath
Ruxolitinib—LTK—polycystic ovary syndrome	0.637	1	CbGaD
Ruxolitinib—BMPR2—ovarian follicle—polycystic ovary syndrome	0.00735	0.0481	CbGeAlD
Ruxolitinib—DCLK3—urine—polycystic ovary syndrome	0.00544	0.0356	CbGeAlD
Ruxolitinib—RPS6KA6—embryo—polycystic ovary syndrome	0.00186	0.0121	CbGeAlD
Ruxolitinib—PLK3—embryo—polycystic ovary syndrome	0.00155	0.0101	CbGeAlD
Ruxolitinib—ANKK1—adrenal gland—polycystic ovary syndrome	0.00148	0.00967	CbGeAlD
Ruxolitinib—PRKG2—pituitary gland—polycystic ovary syndrome	0.00137	0.00897	CbGeAlD
Ruxolitinib—PRKCE—adipose tissue—polycystic ovary syndrome	0.00127	0.00834	CbGeAlD
Ruxolitinib—PLK1—uterus—polycystic ovary syndrome	0.00125	0.00819	CbGeAlD
Ruxolitinib—RPS6KA6—pituitary gland—polycystic ovary syndrome	0.00123	0.00804	CbGeAlD
Ruxolitinib—MAST1—pituitary gland—polycystic ovary syndrome	0.00123	0.00804	CbGeAlD
Ruxolitinib—JAK1—embryo—polycystic ovary syndrome	0.00119	0.00778	CbGeAlD
Ruxolitinib—DCLK1—embryo—polycystic ovary syndrome	0.00119	0.00778	CbGeAlD
Ruxolitinib—CAMK1—adrenal cortex—polycystic ovary syndrome	0.00119	0.00777	CbGeAlD
Ruxolitinib—DCLK3—pituitary gland—polycystic ovary syndrome	0.00116	0.00762	CbGeAlD
Ruxolitinib—PRKCE—adrenal gland—polycystic ovary syndrome	0.00114	0.00748	CbGeAlD
Ruxolitinib—PLK3—endometrium—polycystic ovary syndrome	0.00113	0.00742	CbGeAlD
Ruxolitinib—PLK1—adrenal gland—polycystic ovary syndrome	0.0011	0.00719	CbGeAlD
Ruxolitinib—PRKG2—endocrine gland—polycystic ovary syndrome	0.00106	0.00695	CbGeAlD
Ruxolitinib—CAMK1—endometrium—polycystic ovary syndrome	0.00106	0.00694	CbGeAlD
Ruxolitinib—PLK3—pituitary gland—polycystic ovary syndrome	0.00103	0.00671	CbGeAlD
Ruxolitinib—ROCK1—embryo—polycystic ovary syndrome	0.00102	0.0067	CbGeAlD
Ruxolitinib—PLK3—adipose tissue—polycystic ovary syndrome	0.00102	0.00669	CbGeAlD
Ruxolitinib—PRKCE—endocrine gland—polycystic ovary syndrome	0.000991	0.00649	CbGeAlD
Ruxolitinib—JAK1—adrenal cortex—polycystic ovary syndrome	0.000974	0.00637	CbGeAlD
Ruxolitinib—DCLK3—vagina—polycystic ovary syndrome	0.000964	0.00631	CbGeAlD
Ruxolitinib—CAMK1—pituitary gland—polycystic ovary syndrome	0.000959	0.00628	CbGeAlD
Ruxolitinib—CAMK1—adipose tissue—polycystic ovary syndrome	0.000955	0.00625	CbGeAlD
Ruxolitinib—PLK1—endocrine gland—polycystic ovary syndrome	0.000952	0.00623	CbGeAlD
Ruxolitinib—RPS6KA6—endocrine gland—polycystic ovary syndrome	0.000952	0.00623	CbGeAlD
Ruxolitinib—DAPK2—adrenal cortex—polycystic ovary syndrome	0.000929	0.00608	CbGeAlD
Ruxolitinib—MARK2—adipose tissue—polycystic ovary syndrome	0.000927	0.00607	CbGeAlD
Ruxolitinib—PLK3—adrenal gland—polycystic ovary syndrome	0.000916	0.006	CbGeAlD
Ruxolitinib—JAK1—endometrium—polycystic ovary syndrome	0.000869	0.00569	CbGeAlD
Ruxolitinib—CLK2—adrenal cortex—polycystic ovary syndrome	0.000865	0.00566	CbGeAlD
Ruxolitinib—TAOK2—pituitary gland—polycystic ovary syndrome	0.000862	0.00564	CbGeAlD
Ruxolitinib—TAOK2—adipose tissue—polycystic ovary syndrome	0.000858	0.00562	CbGeAlD
Ruxolitinib—CAMK1—adrenal gland—polycystic ovary syndrome	0.000857	0.00561	CbGeAlD
Ruxolitinib—PLK3—female gonad—polycystic ovary syndrome	0.000854	0.00559	CbGeAlD
Ruxolitinib—PLK3—vagina—polycystic ovary syndrome	0.000849	0.00556	CbGeAlD
Ruxolitinib—MARK2—adrenal gland—polycystic ovary syndrome	0.000832	0.00545	CbGeAlD
Ruxolitinib—DAPK2—endometrium—polycystic ovary syndrome	0.000829	0.00543	CbGeAlD
Ruxolitinib—JAK1—uterus—polycystic ovary syndrome	0.000801	0.00524	CbGeAlD
Ruxolitinib—DCLK1—uterus—polycystic ovary syndrome	0.000801	0.00524	CbGeAlD
Ruxolitinib—CAMK1—female gonad—polycystic ovary syndrome	0.000799	0.00523	CbGeAlD
Ruxolitinib—PLK3—endocrine gland—polycystic ovary syndrome	0.000794	0.0052	CbGeAlD
Ruxolitinib—CAMK1—vagina—polycystic ovary syndrome	0.000794	0.0052	CbGeAlD
Ruxolitinib—JAK3—adipose tissue—polycystic ovary syndrome	0.000789	0.00516	CbGeAlD
Ruxolitinib—JAK1—pituitary gland—polycystic ovary syndrome	0.000787	0.00515	CbGeAlD
Ruxolitinib—DCLK1—pituitary gland—polycystic ovary syndrome	0.000787	0.00515	CbGeAlD
Ruxolitinib—JAK1—adipose tissue—polycystic ovary syndrome	0.000784	0.00513	CbGeAlD
Ruxolitinib—DCLK1—adipose tissue—polycystic ovary syndrome	0.000784	0.00513	CbGeAlD
Ruxolitinib—DAPK3—endometrium—polycystic ovary syndrome	0.00078	0.0051	CbGeAlD
Ruxolitinib—CLK2—endometrium—polycystic ovary syndrome	0.000773	0.00506	CbGeAlD
Ruxolitinib—TAOK2—adrenal gland—polycystic ovary syndrome	0.00077	0.00504	CbGeAlD
Ruxolitinib—CAMK1D—pituitary gland—polycystic ovary syndrome	0.000768	0.00503	CbGeAlD
Ruxolitinib—CAMK1D—adipose tissue—polycystic ovary syndrome	0.000765	0.00501	CbGeAlD
Ruxolitinib—PHKG2—adipose tissue—polycystic ovary syndrome	0.00076	0.00498	CbGeAlD
Ruxolitinib—RET—embryo—polycystic ovary syndrome	0.000756	0.00495	CbGeAlD
Ruxolitinib—DAPK2—adipose tissue—polycystic ovary syndrome	0.000748	0.00489	CbGeAlD
Ruxolitinib—CAMK1—endocrine gland—polycystic ovary syndrome	0.000743	0.00486	CbGeAlD
Ruxolitinib—STK16—pituitary gland—polycystic ovary syndrome	0.000738	0.00483	CbGeAlD
Ruxolitinib—STK16—adipose tissue—polycystic ovary syndrome	0.000735	0.00481	CbGeAlD
Ruxolitinib—HIPK2—adipose tissue—polycystic ovary syndrome	0.000732	0.00479	CbGeAlD
Ruxolitinib—MARK2—endocrine gland—polycystic ovary syndrome	0.000721	0.00472	CbGeAlD
Ruxolitinib—DAPK3—uterus—polycystic ovary syndrome	0.000719	0.0047	CbGeAlD
Ruxolitinib—TAOK2—female gonad—polycystic ovary syndrome	0.000718	0.0047	CbGeAlD
Ruxolitinib—JAK2—embryo—polycystic ovary syndrome	0.000715	0.00468	CbGeAlD
Ruxolitinib—TAOK2—vagina—polycystic ovary syndrome	0.000713	0.00467	CbGeAlD
Ruxolitinib—JAK3—adrenal gland—polycystic ovary syndrome	0.000707	0.00463	CbGeAlD
Ruxolitinib—DAPK3—pituitary gland—polycystic ovary syndrome	0.000706	0.00462	CbGeAlD
Ruxolitinib—JAK1—adrenal gland—polycystic ovary syndrome	0.000703	0.0046	CbGeAlD
Ruxolitinib—DCLK1—adrenal gland—polycystic ovary syndrome	0.000703	0.0046	CbGeAlD
Ruxolitinib—DAPK3—adipose tissue—polycystic ovary syndrome	0.000703	0.0046	CbGeAlD
Ruxolitinib—CLK2—pituitary gland—polycystic ovary syndrome	0.000699	0.00458	CbGeAlD
Ruxolitinib—PLK4—adrenal gland—polycystic ovary syndrome	0.000699	0.00457	CbGeAlD
Ruxolitinib—CLK2—adipose tissue—polycystic ovary syndrome	0.000696	0.00456	CbGeAlD
Ruxolitinib—NUAK2—endometrium—polycystic ovary syndrome	0.000695	0.00455	CbGeAlD
Ruxolitinib—CAMK1D—adrenal gland—polycystic ovary syndrome	0.000686	0.00449	CbGeAlD
Ruxolitinib—PHKG2—adrenal gland—polycystic ovary syndrome	0.000682	0.00446	CbGeAlD
Ruxolitinib—DAPK2—adrenal gland—polycystic ovary syndrome	0.000671	0.00439	CbGeAlD
Ruxolitinib—BMPR2—uterus—polycystic ovary syndrome	0.00067	0.00439	CbGeAlD
Ruxolitinib—STK16—adrenal gland—polycystic ovary syndrome	0.00066	0.00432	CbGeAlD
Ruxolitinib—JAK3—female gonad—polycystic ovary syndrome	0.00066	0.00432	CbGeAlD
Ruxolitinib—BMPR2—pituitary gland—polycystic ovary syndrome	0.000658	0.00431	CbGeAlD
Ruxolitinib—DYRK1A—adipose tissue—polycystic ovary syndrome	0.000658	0.00431	CbGeAlD
Ruxolitinib—HIPK2—adrenal gland—polycystic ovary syndrome	0.000656	0.0043	CbGeAlD
Ruxolitinib—MAP3K7—adrenal cortex—polycystic ovary syndrome	0.000656	0.00429	CbGeAlD
Ruxolitinib—BMPR2—adipose tissue—polycystic ovary syndrome	0.000655	0.00429	CbGeAlD
Ruxolitinib—JAK1—female gonad—polycystic ovary syndrome	0.000655	0.00429	CbGeAlD
Ruxolitinib—JAK1—vagina—polycystic ovary syndrome	0.000651	0.00426	CbGeAlD
Ruxolitinib—DCLK1—vagina—polycystic ovary syndrome	0.000651	0.00426	CbGeAlD
Ruxolitinib—BMP2K—endometrium—polycystic ovary syndrome	0.000651	0.00426	CbGeAlD
Ruxolitinib—CAMK2G—endometrium—polycystic ovary syndrome	0.000651	0.00426	CbGeAlD
Ruxolitinib—LRRK2—endometrium—polycystic ovary syndrome	0.000645	0.00422	CbGeAlD
Ruxolitinib—TYK2—adrenal cortex—polycystic ovary syndrome	0.000644	0.00421	CbGeAlD
Ruxolitinib—CAMK1D—female gonad—polycystic ovary syndrome	0.00064	0.00419	CbGeAlD
Ruxolitinib—PHKG2—female gonad—polycystic ovary syndrome	0.000636	0.00416	CbGeAlD
Ruxolitinib—CAMK1D—vagina—polycystic ovary syndrome	0.000636	0.00416	CbGeAlD
Ruxolitinib—MKNK2—adrenal cortex—polycystic ovary syndrome	0.000635	0.00416	CbGeAlD
Ruxolitinib—DAPK3—adrenal gland—polycystic ovary syndrome	0.00063	0.00413	CbGeAlD
Ruxolitinib—NUAK2—pituitary gland—polycystic ovary syndrome	0.000629	0.00412	CbGeAlD
Ruxolitinib—NUAK2—adipose tissue—polycystic ovary syndrome	0.000626	0.0041	CbGeAlD
Ruxolitinib—DAPK2—female gonad—polycystic ovary syndrome	0.000625	0.00409	CbGeAlD
Ruxolitinib—CLK2—adrenal gland—polycystic ovary syndrome	0.000625	0.00409	CbGeAlD
Ruxolitinib—DAPK2—vagina—polycystic ovary syndrome	0.000621	0.00407	CbGeAlD
Ruxolitinib—STK16—female gonad—polycystic ovary syndrome	0.000615	0.00403	CbGeAlD
Ruxolitinib—JAK3—endocrine gland—polycystic ovary syndrome	0.000613	0.00402	CbGeAlD
Ruxolitinib—HIPK2—female gonad—polycystic ovary syndrome	0.000612	0.00401	CbGeAlD
Ruxolitinib—STK16—vagina—polycystic ovary syndrome	0.000611	0.004	CbGeAlD
Ruxolitinib—JAK1—endocrine gland—polycystic ovary syndrome	0.000609	0.00399	CbGeAlD
Ruxolitinib—DCLK1—endocrine gland—polycystic ovary syndrome	0.000609	0.00399	CbGeAlD
Ruxolitinib—PLK4—endocrine gland—polycystic ovary syndrome	0.000606	0.00397	CbGeAlD
Ruxolitinib—CAMK2G—uterus—polycystic ovary syndrome	0.0006	0.00393	CbGeAlD
Ruxolitinib—CAMK1D—endocrine gland—polycystic ovary syndrome	0.000595	0.00389	CbGeAlD
Ruxolitinib—PHKG2—endocrine gland—polycystic ovary syndrome	0.000591	0.00387	CbGeAlD
Ruxolitinib—DYRK1A—adrenal gland—polycystic ovary syndrome	0.00059	0.00386	CbGeAlD
Ruxolitinib—CYP3A4—urine—polycystic ovary syndrome	0.00059	0.00386	CbGeAlD
Ruxolitinib—CAMK2G—pituitary gland—polycystic ovary syndrome	0.000589	0.00386	CbGeAlD
Ruxolitinib—BMPR2—adrenal gland—polycystic ovary syndrome	0.000588	0.00385	CbGeAlD
Ruxolitinib—DAPK3—female gonad—polycystic ovary syndrome	0.000588	0.00385	CbGeAlD
Ruxolitinib—CAMK2G—adipose tissue—polycystic ovary syndrome	0.000587	0.00384	CbGeAlD
Ruxolitinib—BMP2K—adipose tissue—polycystic ovary syndrome	0.000587	0.00384	CbGeAlD
Ruxolitinib—MAP3K7—endometrium—polycystic ovary syndrome	0.000585	0.00383	CbGeAlD
Ruxolitinib—DAPK3—vagina—polycystic ovary syndrome	0.000584	0.00382	CbGeAlD
Ruxolitinib—LRRK2—pituitary gland—polycystic ovary syndrome	0.000584	0.00382	CbGeAlD
Ruxolitinib—CLK2—female gonad—polycystic ovary syndrome	0.000582	0.00381	CbGeAlD
Ruxolitinib—LRRK2—adipose tissue—polycystic ovary syndrome	0.000581	0.00381	CbGeAlD
Ruxolitinib—CLK2—vagina—polycystic ovary syndrome	0.000579	0.00379	CbGeAlD
Ruxolitinib—TYK2—endometrium—polycystic ovary syndrome	0.000575	0.00376	CbGeAlD
Ruxolitinib—STK16—endocrine gland—polycystic ovary syndrome	0.000572	0.00374	CbGeAlD
Ruxolitinib—HIPK2—endocrine gland—polycystic ovary syndrome	0.000569	0.00372	CbGeAlD
Ruxolitinib—MKNK2—endometrium—polycystic ovary syndrome	0.000567	0.00371	CbGeAlD
Ruxolitinib—MAP3K3—adrenal cortex—polycystic ovary syndrome	0.000565	0.0037	CbGeAlD
Ruxolitinib—ROCK1—female gonad—polycystic ovary syndrome	0.000564	0.00369	CbGeAlD
Ruxolitinib—NUAK2—adrenal gland—polycystic ovary syndrome	0.000562	0.00368	CbGeAlD
Ruxolitinib—DYRK1A—female gonad—polycystic ovary syndrome	0.00055	0.0036	CbGeAlD
Ruxolitinib—BMPR2—female gonad—polycystic ovary syndrome	0.000548	0.00359	CbGeAlD
Ruxolitinib—DAPK3—endocrine gland—polycystic ovary syndrome	0.000547	0.00358	CbGeAlD
Ruxolitinib—BMPR2—vagina—polycystic ovary syndrome	0.000545	0.00357	CbGeAlD
Ruxolitinib—MAP3K2—uterus—polycystic ovary syndrome	0.000545	0.00357	CbGeAlD
Ruxolitinib—CLK2—endocrine gland—polycystic ovary syndrome	0.000542	0.00355	CbGeAlD
Ruxolitinib—MAP3K7—uterus—polycystic ovary syndrome	0.00054	0.00353	CbGeAlD
Ruxolitinib—MAP3K2—adipose tissue—polycystic ovary syndrome	0.000533	0.00349	CbGeAlD
Ruxolitinib—MAP3K7—pituitary gland—polycystic ovary syndrome	0.00053	0.00347	CbGeAlD
Ruxolitinib—TYK2—uterus—polycystic ovary syndrome	0.00053	0.00347	CbGeAlD
Ruxolitinib—MAP3K7—adipose tissue—polycystic ovary syndrome	0.000528	0.00345	CbGeAlD
Ruxolitinib—CAMK2G—adrenal gland—polycystic ovary syndrome	0.000526	0.00344	CbGeAlD
Ruxolitinib—BMP2K—adrenal gland—polycystic ovary syndrome	0.000526	0.00344	CbGeAlD
Ruxolitinib—ROCK1—endocrine gland—polycystic ovary syndrome	0.000525	0.00344	CbGeAlD
Ruxolitinib—NUAK2—female gonad—polycystic ovary syndrome	0.000524	0.00343	CbGeAlD
Ruxolitinib—JAK2—endometrium—polycystic ovary syndrome	0.000523	0.00342	CbGeAlD
Ruxolitinib—MKNK2—uterus—polycystic ovary syndrome	0.000523	0.00342	CbGeAlD
Ruxolitinib—LRRK2—adrenal gland—polycystic ovary syndrome	0.000521	0.00341	CbGeAlD
Ruxolitinib—NUAK2—vagina—polycystic ovary syndrome	0.000521	0.00341	CbGeAlD
Ruxolitinib—TYK2—pituitary gland—polycystic ovary syndrome	0.00052	0.00341	CbGeAlD
Ruxolitinib—TYK2—adipose tissue—polycystic ovary syndrome	0.000518	0.00339	CbGeAlD
Ruxolitinib—TAOK3—adrenal cortex—polycystic ovary syndrome	0.000515	0.00337	CbGeAlD
Ruxolitinib—MKNK2—pituitary gland—polycystic ovary syndrome	0.000513	0.00336	CbGeAlD
Ruxolitinib—DYRK1A—endocrine gland—polycystic ovary syndrome	0.000512	0.00335	CbGeAlD
Ruxolitinib—MKNK2—adipose tissue—polycystic ovary syndrome	0.000511	0.00335	CbGeAlD
Ruxolitinib—IRAK1—adipose tissue—polycystic ovary syndrome	0.000511	0.00335	CbGeAlD
Ruxolitinib—BMPR2—endocrine gland—polycystic ovary syndrome	0.00051	0.00334	CbGeAlD
Ruxolitinib—MAP3K3—endometrium—polycystic ovary syndrome	0.000504	0.0033	CbGeAlD
Ruxolitinib—RET—pituitary gland—polycystic ovary syndrome	0.000501	0.00328	CbGeAlD
Ruxolitinib—BMP2K—female gonad—polycystic ovary syndrome	0.000491	0.00321	CbGeAlD
Ruxolitinib—CAMK2G—female gonad—polycystic ovary syndrome	0.000491	0.00321	CbGeAlD
Ruxolitinib—BMP2K—vagina—polycystic ovary syndrome	0.000488	0.00319	CbGeAlD
Ruxolitinib—CAMK2G—vagina—polycystic ovary syndrome	0.000488	0.00319	CbGeAlD
Ruxolitinib—LRRK2—female gonad—polycystic ovary syndrome	0.000486	0.00318	CbGeAlD
Ruxolitinib—LRRK2—vagina—polycystic ovary syndrome	0.000483	0.00316	CbGeAlD
Ruxolitinib—MAP3K2—adrenal gland—polycystic ovary syndrome	0.000478	0.00313	CbGeAlD
Ruxolitinib—JAK2—pituitary gland—polycystic ovary syndrome	0.000473	0.0031	CbGeAlD
Ruxolitinib—MAP3K7—adrenal gland—polycystic ovary syndrome	0.000473	0.0031	CbGeAlD
Ruxolitinib—JAK2—adipose tissue—polycystic ovary syndrome	0.000471	0.00309	CbGeAlD
Ruxolitinib—TYK2—adrenal gland—polycystic ovary syndrome	0.000465	0.00304	CbGeAlD
Ruxolitinib—TAOK3—endometrium—polycystic ovary syndrome	0.00046	0.00301	CbGeAlD
Ruxolitinib—IRAK1—adrenal gland—polycystic ovary syndrome	0.000459	0.003	CbGeAlD
Ruxolitinib—MKNK2—adrenal gland—polycystic ovary syndrome	0.000459	0.003	CbGeAlD
Ruxolitinib—BMP2K—endocrine gland—polycystic ovary syndrome	0.000456	0.00299	CbGeAlD
Ruxolitinib—CAMK2G—endocrine gland—polycystic ovary syndrome	0.000456	0.00299	CbGeAlD
Ruxolitinib—MAP3K3—pituitary gland—polycystic ovary syndrome	0.000456	0.00299	CbGeAlD
Ruxolitinib—MAP3K3—adipose tissue—polycystic ovary syndrome	0.000454	0.00297	CbGeAlD
Ruxolitinib—LRRK2—endocrine gland—polycystic ovary syndrome	0.000452	0.00296	CbGeAlD
Ruxolitinib—RET—adrenal gland—polycystic ovary syndrome	0.000447	0.00293	CbGeAlD
Ruxolitinib—MAP3K2—female gonad—polycystic ovary syndrome	0.000445	0.00292	CbGeAlD
Ruxolitinib—MAP3K7—female gonad—polycystic ovary syndrome	0.000441	0.00289	CbGeAlD
Ruxolitinib—MAP3K7—vagina—polycystic ovary syndrome	0.000439	0.00287	CbGeAlD
Ruxolitinib—TYK2—female gonad—polycystic ovary syndrome	0.000433	0.00284	CbGeAlD
Ruxolitinib—TYK2—vagina—polycystic ovary syndrome	0.000431	0.00282	CbGeAlD
Ruxolitinib—MKNK2—female gonad—polycystic ovary syndrome	0.000428	0.0028	CbGeAlD
Ruxolitinib—IRAK1—female gonad—polycystic ovary syndrome	0.000428	0.0028	CbGeAlD
Ruxolitinib—MKNK2—vagina—polycystic ovary syndrome	0.000425	0.00278	CbGeAlD
Ruxolitinib—TAOK3—uterus—polycystic ovary syndrome	0.000424	0.00277	CbGeAlD
Ruxolitinib—JAK2—adrenal gland—polycystic ovary syndrome	0.000423	0.00277	CbGeAlD
Ruxolitinib—TAOK3—pituitary gland—polycystic ovary syndrome	0.000416	0.00272	CbGeAlD
Ruxolitinib—MAP3K2—endocrine gland—polycystic ovary syndrome	0.000414	0.00271	CbGeAlD
Ruxolitinib—TAOK3—adipose tissue—polycystic ovary syndrome	0.000414	0.00271	CbGeAlD
Ruxolitinib—MAP3K3—adrenal gland—polycystic ovary syndrome	0.000408	0.00267	CbGeAlD
Ruxolitinib—TYK2—endocrine gland—polycystic ovary syndrome	0.000403	0.00264	CbGeAlD
Ruxolitinib—MKNK2—endocrine gland—polycystic ovary syndrome	0.000398	0.0026	CbGeAlD
Ruxolitinib—JAK2—female gonad—polycystic ovary syndrome	0.000394	0.00258	CbGeAlD
Ruxolitinib—JAK2—vagina—polycystic ovary syndrome	0.000392	0.00257	CbGeAlD
Ruxolitinib—RET—endocrine gland—polycystic ovary syndrome	0.000388	0.00254	CbGeAlD
Ruxolitinib—MAP3K3—female gonad—polycystic ovary syndrome	0.00038	0.00249	CbGeAlD
Ruxolitinib—MAP3K3—vagina—polycystic ovary syndrome	0.000378	0.00247	CbGeAlD
Ruxolitinib—TAOK3—adrenal gland—polycystic ovary syndrome	0.000372	0.00243	CbGeAlD
Ruxolitinib—JAK2—endocrine gland—polycystic ovary syndrome	0.000367	0.0024	CbGeAlD
Ruxolitinib—MAP3K3—endocrine gland—polycystic ovary syndrome	0.000353	0.00231	CbGeAlD
Ruxolitinib—TAOK3—female gonad—polycystic ovary syndrome	0.000346	0.00227	CbGeAlD
Ruxolitinib—TAOK3—vagina—polycystic ovary syndrome	0.000344	0.00225	CbGeAlD
Ruxolitinib—TAOK3—endocrine gland—polycystic ovary syndrome	0.000322	0.00211	CbGeAlD
Ruxolitinib—CYP3A4—endocrine gland—polycystic ovary syndrome	9.79e-05	0.000641	CbGeAlD
Ruxolitinib—JAK2—Signaling Pathways—RBP4—polycystic ovary syndrome	5.8e-06	2.76e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—GHRL—polycystic ovary syndrome	5.8e-06	2.76e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—PLAT—polycystic ovary syndrome	5.8e-06	2.76e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—AKT2—polycystic ovary syndrome	5.8e-06	2.76e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—polycystic ovary syndrome	5.78e-06	2.75e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—INS—polycystic ovary syndrome	5.77e-06	2.75e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—NCOR1—polycystic ovary syndrome	5.75e-06	2.74e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—SLC2A4—polycystic ovary syndrome	5.75e-06	2.73e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—GNAS—polycystic ovary syndrome	5.72e-06	2.72e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—ATF1—polycystic ovary syndrome	5.7e-06	2.71e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—IRS2—polycystic ovary syndrome	5.69e-06	2.71e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—CRP—polycystic ovary syndrome	5.69e-06	2.71e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Developmental Biology—VEGFA—polycystic ovary syndrome	5.67e-06	2.7e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—NCOR1—polycystic ovary syndrome	5.65e-06	2.69e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—NRG1—polycystic ovary syndrome	5.64e-06	2.69e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—PLAT—polycystic ovary syndrome	5.63e-06	2.68e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—GHRL—polycystic ovary syndrome	5.63e-06	2.68e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—IRS2—polycystic ovary syndrome	5.62e-06	2.67e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—POMC—polycystic ovary syndrome	5.6e-06	2.66e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—AKT2—polycystic ovary syndrome	5.58e-06	2.65e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—INS—polycystic ovary syndrome	5.57e-06	2.65e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—TCF7L2—polycystic ovary syndrome	5.56e-06	2.65e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—NRG1—polycystic ovary syndrome	5.55e-06	2.64e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—ATF1—polycystic ovary syndrome	5.54e-06	2.64e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—IRS2—polycystic ovary syndrome	5.52e-06	2.63e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—CRP—polycystic ovary syndrome	5.52e-06	2.63e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—LEP—polycystic ovary syndrome	5.5e-06	2.62e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Axon guidance—IL6—polycystic ovary syndrome	5.49e-06	2.61e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—PRL—polycystic ovary syndrome	5.48e-06	2.61e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—YAP1—polycystic ovary syndrome	5.42e-06	2.58e-05	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—VEGFA—polycystic ovary syndrome	5.42e-06	2.58e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—TCF7L2—polycystic ovary syndrome	5.4e-06	2.57e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—IGF1—polycystic ovary syndrome	5.38e-06	2.56e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—AKT2—polycystic ovary syndrome	5.38e-06	2.56e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—ATF1—polycystic ovary syndrome	5.37e-06	2.56e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—MTHFR—polycystic ovary syndrome	5.36e-06	2.55e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—IRS2—polycystic ovary syndrome	5.35e-06	2.55e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—CRP—polycystic ovary syndrome	5.35e-06	2.55e-05	CbGpPWpGaD
Ruxolitinib—PHKG2—Disease—IL6—polycystic ovary syndrome	5.35e-06	2.55e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—GAB1—polycystic ovary syndrome	5.34e-06	2.54e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Developmental Biology—IL6—polycystic ovary syndrome	5.31e-06	2.53e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—NMNAT3—polycystic ovary syndrome	5.3e-06	2.52e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—SERPINE1—polycystic ovary syndrome	5.3e-06	2.52e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—BCL2—polycystic ovary syndrome	5.28e-06	2.51e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—NGFR—polycystic ovary syndrome	5.26e-06	2.51e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—TCF7L2—polycystic ovary syndrome	5.24e-06	2.49e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Developmental Biology—IL6—polycystic ovary syndrome	5.22e-06	2.49e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—PRL—polycystic ovary syndrome	5.22e-06	2.48e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—SERPINE1—polycystic ovary syndrome	5.11e-06	2.43e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—INSR—polycystic ovary syndrome	5.11e-06	2.43e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—NGFR—polycystic ovary syndrome	5.11e-06	2.43e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—IRS2—polycystic ovary syndrome	5.1e-06	2.42e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—POMC—polycystic ovary syndrome	5.08e-06	2.42e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—BCL2—polycystic ovary syndrome	5.07e-06	2.41e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—PRL—polycystic ovary syndrome	5.06e-06	2.41e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—IL18—polycystic ovary syndrome	4.99e-06	2.38e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—IRS1—polycystic ovary syndrome	4.96e-06	2.36e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—NGFR—polycystic ovary syndrome	4.96e-06	2.36e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—ADRB2—polycystic ovary syndrome	4.95e-06	2.36e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—PRL—polycystic ovary syndrome	4.91e-06	2.34e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—IRS1—polycystic ovary syndrome	4.91e-06	2.33e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—NRG1—polycystic ovary syndrome	4.88e-06	2.32e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—AKT2—polycystic ovary syndrome	4.88e-06	2.32e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—AKR1C3—polycystic ovary syndrome	4.86e-06	2.31e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—LPCAT2—polycystic ovary syndrome	4.85e-06	2.31e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—SUOX—polycystic ovary syndrome	4.85e-06	2.31e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—IRS2—polycystic ovary syndrome	4.83e-06	2.3e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—IRS1—polycystic ovary syndrome	4.82e-06	2.29e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—ADRB2—polycystic ovary syndrome	4.8e-06	2.29e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—TNRC6B—polycystic ovary syndrome	4.78e-06	2.27e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—IRS2—polycystic ovary syndrome	4.75e-06	2.26e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—PGR—polycystic ovary syndrome	4.73e-06	2.25e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—LEP—polycystic ovary syndrome	4.73e-06	2.25e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—POMC—polycystic ovary syndrome	4.72e-06	2.25e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—INS—polycystic ovary syndrome	4.7e-06	2.24e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Innate Immune System—IL6—polycystic ovary syndrome	4.69e-06	2.23e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Cytokine Signaling in Immune system—IL6—polycystic ovary syndrome	4.68e-06	2.23e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—IRS1—polycystic ovary syndrome	4.67e-06	2.22e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—ADRB2—polycystic ovary syndrome	4.66e-06	2.22e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—LEP—polycystic ovary syndrome	4.65e-06	2.21e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by NGF—IL6—polycystic ovary syndrome	4.6e-06	2.19e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—AKT2—polycystic ovary syndrome	4.59e-06	2.19e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—NCOR1—polycystic ovary syndrome	4.59e-06	2.19e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—GNAS—polycystic ovary syndrome	4.59e-06	2.18e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—IGF1—polycystic ovary syndrome	4.54e-06	2.16e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—AKT2—polycystic ovary syndrome	4.54e-06	2.16e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—NRG1—polycystic ovary syndrome	4.51e-06	2.15e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ISYNA1—polycystic ovary syndrome	4.51e-06	2.15e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Biological oxidations—POMC—polycystic ovary syndrome	4.49e-06	2.14e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—AKT2—polycystic ovary syndrome	4.46e-06	2.12e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—GNAS—polycystic ovary syndrome	4.46e-06	2.12e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—IRS1—polycystic ovary syndrome	4.45e-06	2.12e-05	CbGpPWpGaD
Ruxolitinib—PRKG2—Signaling Pathways—IL6—polycystic ovary syndrome	4.41e-06	2.1e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—PLAT—polycystic ovary syndrome	4.4e-06	2.09e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—GHRL—polycystic ovary syndrome	4.4e-06	2.09e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—NCOR1—polycystic ovary syndrome	4.37e-06	2.08e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—AKT2—polycystic ovary syndrome	4.33e-06	2.06e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—GNAS—polycystic ovary syndrome	4.32e-06	2.06e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—SERPINE1—polycystic ovary syndrome	4.31e-06	2.05e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—VEGFA—polycystic ovary syndrome	4.29e-06	2.04e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—NRG1—polycystic ovary syndrome	4.29e-06	2.04e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—INS—polycystic ovary syndrome	4.26e-06	2.03e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—NCOR1—polycystic ovary syndrome	4.24e-06	2.02e-05	CbGpPWpGaD
Ruxolitinib—JAK2—GPCR downstream signaling—POMC—polycystic ovary syndrome	4.24e-06	2.02e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—IRS1—polycystic ovary syndrome	4.22e-06	2.01e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—VEGFA—polycystic ovary syndrome	4.21e-06	2.01e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—ATF1—polycystic ovary syndrome	4.2e-06	2e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—CRP—polycystic ovary syndrome	4.18e-06	1.99e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—IRS2—polycystic ovary syndrome	4.18e-06	1.99e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—NRG1—polycystic ovary syndrome	4.17e-06	1.98e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Axon guidance—IL6—polycystic ovary syndrome	4.16e-06	1.98e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—IRS1—polycystic ovary syndrome	4.15e-06	1.98e-05	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—IL6—polycystic ovary syndrome	4.14e-06	1.97e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—AKT2—polycystic ovary syndrome	4.12e-06	1.96e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling by GPCR—IL6—polycystic ovary syndrome	4.12e-06	1.96e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—NCOR1—polycystic ovary syndrome	4.12e-06	1.96e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—TCF7L2—polycystic ovary syndrome	4.09e-06	1.95e-05	CbGpPWpGaD
Ruxolitinib—JAK2—GPCR downstream signaling—AKT2—polycystic ovary syndrome	4.07e-06	1.94e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—POMC—polycystic ovary syndrome	4.06e-06	1.93e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—MTHFR—polycystic ovary syndrome	4.06e-06	1.93e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—INS—polycystic ovary syndrome	4.04e-06	1.92e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—NRG1—polycystic ovary syndrome	4.04e-06	1.92e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—BCL2—polycystic ovary syndrome	4.01e-06	1.91e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—POMC—polycystic ovary syndrome	4e-06	1.9e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—INS—polycystic ovary syndrome	3.97e-06	1.89e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Developmental Biology—IL6—polycystic ovary syndrome	3.92e-06	1.87e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—SERPINE1—polycystic ovary syndrome	3.91e-06	1.86e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—IGF1—polycystic ovary syndrome	3.91e-06	1.86e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—AKT2—polycystic ovary syndrome	3.91e-06	1.86e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—BCL2—polycystic ovary syndrome	3.9e-06	1.85e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—NGFR—polycystic ovary syndrome	3.87e-06	1.84e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—IRS2—polycystic ovary syndrome	3.86e-06	1.84e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—POMC—polycystic ovary syndrome	3.85e-06	1.83e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—IGF1—polycystic ovary syndrome	3.84e-06	1.83e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—AKT2—polycystic ovary syndrome	3.84e-06	1.83e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—PRL—polycystic ovary syndrome	3.84e-06	1.83e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—AKR1C2—polycystic ovary syndrome	3.83e-06	1.82e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—TEAD2—polycystic ovary syndrome	3.83e-06	1.82e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—BCL2—polycystic ovary syndrome	3.78e-06	1.8e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—IL6—polycystic ovary syndrome	3.76e-06	1.79e-05	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—IL6—polycystic ovary syndrome	3.75e-06	1.78e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—SERPINE1—polycystic ovary syndrome	3.71e-06	1.77e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—AKT2—polycystic ovary syndrome	3.7e-06	1.76e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—IRS2—polycystic ovary syndrome	3.68e-06	1.75e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—IRS1—polycystic ovary syndrome	3.65e-06	1.74e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—SERPINE1—polycystic ovary syndrome	3.65e-06	1.74e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—ADRB2—polycystic ovary syndrome	3.64e-06	1.73e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—LEP—polycystic ovary syndrome	3.6e-06	1.71e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—IRS2—polycystic ovary syndrome	3.57e-06	1.7e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Innate Immune System—IL6—polycystic ovary syndrome	3.57e-06	1.7e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—VEGFA—polycystic ovary syndrome	3.52e-06	1.67e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—LEP—polycystic ovary syndrome	3.49e-06	1.66e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling by GPCR—IL6—polycystic ovary syndrome	3.47e-06	1.65e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Disease—IL6—polycystic ovary syndrome	3.47e-06	1.65e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Innate Immune System—IL6—polycystic ovary syndrome	3.46e-06	1.65e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—IRS2—polycystic ovary syndrome	3.46e-06	1.65e-05	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—IL6—polycystic ovary syndrome	3.45e-06	1.64e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—LEP—polycystic ovary syndrome	3.39e-06	1.61e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—AKT2—polycystic ovary syndrome	3.38e-06	1.61e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—GNAS—polycystic ovary syndrome	3.38e-06	1.61e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—IRS1—polycystic ovary syndrome	3.37e-06	1.6e-05	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—IL6—polycystic ovary syndrome	3.37e-06	1.6e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Innate Immune System—IL6—polycystic ovary syndrome	3.36e-06	1.6e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—INS—polycystic ovary syndrome	3.23e-06	1.54e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—NCOR1—polycystic ovary syndrome	3.22e-06	1.53e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PNPLA2—polycystic ovary syndrome	3.21e-06	1.53e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—IRS1—polycystic ovary syndrome	3.21e-06	1.53e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—IL6—polycystic ovary syndrome	3.17e-06	1.51e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—NRG1—polycystic ovary syndrome	3.16e-06	1.5e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—AKT2—polycystic ovary syndrome	3.12e-06	1.49e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—IRS1—polycystic ovary syndrome	3.12e-06	1.48e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—POMC—polycystic ovary syndrome	3.09e-06	1.47e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—INS—polycystic ovary syndrome	3.07e-06	1.46e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—SRD5A1—polycystic ovary syndrome	3.04e-06	1.45e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—IRS1—polycystic ovary syndrome	3.02e-06	1.44e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—POMC—polycystic ovary syndrome	3e-06	1.43e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by GPCR—IL6—polycystic ovary syndrome	2.99e-06	1.42e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—INS—polycystic ovary syndrome	2.98e-06	1.42e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—IGF1—polycystic ovary syndrome	2.97e-06	1.41e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—IL6—polycystic ovary syndrome	2.97e-06	1.41e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—AKT2—polycystic ovary syndrome	2.97e-06	1.41e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.97e-06	1.41e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—SERPINE1—polycystic ovary syndrome	2.97e-06	1.41e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—BCL2—polycystic ovary syndrome	2.95e-06	1.41e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—IL6—polycystic ovary syndrome	2.94e-06	1.4e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—POMC—polycystic ovary syndrome	2.91e-06	1.38e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—STAR—polycystic ovary syndrome	2.9e-06	1.38e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—INS—polycystic ovary syndrome	2.89e-06	1.38e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—IGF1—polycystic ovary syndrome	2.89e-06	1.37e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—AKT2—polycystic ovary syndrome	2.88e-06	1.37e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.82e-06	1.34e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—IGF1—polycystic ovary syndrome	2.8e-06	1.33e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—AKT2—polycystic ovary syndrome	2.8e-06	1.33e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.74e-06	1.3e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—IL6—polycystic ovary syndrome	2.73e-06	1.3e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—IRS2—polycystic ovary syndrome	2.7e-06	1.29e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.66e-06	1.26e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—LEP—polycystic ovary syndrome	2.65e-06	1.26e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—IL6—polycystic ovary syndrome	2.62e-06	1.25e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—HMMR—polycystic ovary syndrome	2.59e-06	1.23e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.55e-06	1.21e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—IL6—polycystic ovary syndrome	2.52e-06	1.2e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.51e-06	1.19e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—HSD3B1—polycystic ovary syndrome	2.47e-06	1.18e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—IL6—polycystic ovary syndrome	2.43e-06	1.16e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—IRS1—polycystic ovary syndrome	2.36e-06	1.12e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—POMC—polycystic ovary syndrome	2.27e-06	1.08e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—INS—polycystic ovary syndrome	2.26e-06	1.08e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—LHB—polycystic ovary syndrome	2.25e-06	1.07e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—IL6—polycystic ovary syndrome	2.21e-06	1.05e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—HSD3B2—polycystic ovary syndrome	2.2e-06	1.05e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—IGF1—polycystic ovary syndrome	2.19e-06	1.04e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—AKT2—polycystic ovary syndrome	2.19e-06	1.04e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—AKR1C1—polycystic ovary syndrome	2.13e-06	1.01e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—IL6—polycystic ovary syndrome	2.08e-06	9.88e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.08e-06	9.88e-06	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—IL6—polycystic ovary syndrome	2.05e-06	9.77e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—IL6—polycystic ovary syndrome	2.02e-06	9.59e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—SULT2A1—polycystic ovary syndrome	1.96e-06	9.34e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—IL6—polycystic ovary syndrome	1.96e-06	9.31e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.94e-06	9.24e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—RRM2—polycystic ovary syndrome	1.9e-06	9.04e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.88e-06	8.97e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—IL6—polycystic ovary syndrome	1.86e-06	8.86e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—YAP1—polycystic ovary syndrome	1.83e-06	8.72e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.83e-06	8.7e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—IL6—polycystic ovary syndrome	1.77e-06	8.4e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—NAMPT—polycystic ovary syndrome	1.76e-06	8.37e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CYP11A1—polycystic ovary syndrome	1.74e-06	8.27e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—IL6—polycystic ovary syndrome	1.74e-06	8.26e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—IL6—polycystic ovary syndrome	1.67e-06	7.96e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—AKR1C3—polycystic ovary syndrome	1.64e-06	7.81e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CYP17A1—polycystic ovary syndrome	1.62e-06	7.69e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—IL6—polycystic ovary syndrome	1.53e-06	7.27e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.43e-06	6.8e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—IL6—polycystic ovary syndrome	1.41e-06	6.71e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—TH—polycystic ovary syndrome	1.4e-06	6.65e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—SLC2A4—polycystic ovary syndrome	1.36e-06	6.47e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—IL6—polycystic ovary syndrome	1.34e-06	6.39e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—IL6—polycystic ovary syndrome	1.3e-06	6.2e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CYP19A1—polycystic ovary syndrome	1.28e-06	6.08e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—IL6—polycystic ovary syndrome	1.26e-06	6.02e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GNAS—polycystic ovary syndrome	1.14e-06	5.43e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—NCOR1—polycystic ovary syndrome	1.09e-06	5.17e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CYP1A1—polycystic ovary syndrome	1.03e-06	4.9e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—IL6—polycystic ovary syndrome	9.88e-07	4.7e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—MTHFR—polycystic ovary syndrome	9.61e-07	4.57e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PPARG—polycystic ovary syndrome	7.79e-07	3.71e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—POMC—polycystic ovary syndrome	7.68e-07	3.66e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—INS—polycystic ovary syndrome	7.64e-07	3.64e-06	CbGpPWpGaD
